When Your Sponsor Gets Acquired Mid-Trial, Your Site Pays the Operational Price
Lilly's $7.8B Centessa acquisition closes June 24—here's what site coordinators and ops leads must do before the IND transfers...
Revolution Medicines Opens RASolute 305 Trial of Zoldonrasib in RAS G12D Pancreatic Cancer
Revolution Medicines opens RASolute 305 Trial of zoldonrasib in RAS G12D pancreatic cancer, testing the G12D-selective inhibitor in the...
Obesity Trials Are Optimized to Win Approval, Not to Predict Real-World Use
Nature Medicine's 2026 analysis exposes why obesity drug trials maximizing weight loss endpoints produce results that collapse on contact...
Autonomous AI Agents Can Outperform Physicians. That’s Not the Hard Part.
MIRA beat physicians on diagnostic accuracy. AMIE matched them across 100 cases. Now comes the real test: whether regulated...
Zoll Medical’s FDA Warning Letter Reveals the QC Failure Sponsors Keep Funding
FDA's April 2026 warning letter to Zoll Medical exposes quality control and MDR violations at a cardiopulmonary device maker...
TSC-101 Achieves Complete Donor Chimerism in 93% of AML Patients in Phase 1
TSC-101 achieves complete donor chimerism in 93% of AML patients in Phase 1, with manufacturing success rate at 90%...
Nature Medicine’s June 2026 Benchmark Study Reveals General-Purpose LLMs Outperform FDA-Cleared Clinical AI — and Exposes a Validation Gap Regulators Have Not Closed
A Nature Medicine study finds GPT-5.2, Gemini 3.1 Pro, and Claude Opus 4.6 outperform FDA-cleared clinical AI tools on...
Atsena’s ATSN-201 Gene Therapy Enrolls Rapidly in Phase 3 Trial for X-Linked Retinoschisis
ATSN-201 gene therapy enrolls 10% of its 76-patient Phase 3 trial within weeks, targeting BLA filing in late 2028...
Boehringer Ingelheim launches three Phase III trials for obrixtamig and zongertinib
Boehringer Ingelheim launches three Phase III trials for obrixtamig and zongertinib across neuroendocrine carcinoma and HER2-mutant NSCLC.
Regeneron’s Cemdisiran Accepted for FDA Review in Generalized Myasthenia Gravis
Regeneron's cemdisiran accepted for FDA review in generalized myasthenia gravis, targeting November 2026 action date via Priority Review Voucher.